RT Journal Article
SR Electronic
T1 The validation of the original and modified Caprini score in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.22.20137075
DO 10.1101/2020.06.22.20137075
A1 Tsaplin, Sergey
A1 Schastlivtsev, Ilya
A1 Lobastov, Kirill
A1 Zhuravlev, Sergey
A1 Barinov, Victor
A1 Caprini, Joseph A
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137075.abstract
AB Objective The study aimed to validate the original Caprini score and its modifications considering coronavirus disease (COVID-19) as a severe prothrombotic condition in patients admitted to the hospital with confirmed infection.Methods The relevant data were extracted from the electronic medical records with the implemented Caprini score and were evaluated retrospectively. The score was calculated twice: by the physician at the admission and by the investigator at discharge or after death. The second calculation at discharge, considered additional risk factors that occurred during inpatient treatment. Besides the original Caprini score (a version of 2005), the modified version added the elevation of D-dimer and specific scores for COVID-19 as follows: 2 points for asymptomatic, 3 points for symptomatic and 5 points for symptomatic infection with positive D-dimer, were evaluated in a retrospective manner. The primary endpoint was symptomatic venous thromboembolism (VTE) confirmed by appropriate imaging testing or dissection. The secondary endpoint included the unfavorable outcome as a combination of symptomatic VTE, admission to the intensive care unit, the requirement for invasive mechanical ventilation, and death. The association of eight different versions of the Caprini score with outcomes was evaluated.Results Totally 168 patients (83 males and 85 females at the age of 58.3±12.7 years old) were admitted to the hospital between April 30 and May 29, 2020, and were discharged or died up to the time of data analysis. The original Caprini score varied between 2-12 (5.4±1.8) at the admission and between 2-15 (5.9±2.5) at discharge or death. The presence of the virus increased these scores and resulted in an increased score with the maximal value for those including COVID-19 points (10.0±3.0). Patients received prophylactic (2.4%), intermediate (76.8%), or therapeutic (20.8%) doses of enoxaparin. Despite this, the symptomatic VTE was detected in 11 (6.5%) and unfavorable outcomes in 31 (18.5%) patients. The Caprini score of all eight versions demonstrated a significant association with VTE with the highest predictability for the original scale when assessed at discharge. Supplementation of the original score by elevated D-dimer improved predictability only at the admission. Four versions of the Caprini score calculated at the admission had a significant correlation with the unfavorable outcome with the minor advantages of specific COVID-19 points.Conclusion The study identified a significant correlation between the Caprini score and the risk of VTE or unfavorable outcomes in COVID-19 patients. All models, including specific COVID-19 scores, showed high predictability with minor differences.Type of Research A single-center retrospective analysis of prospectively collected data.Key Findings The original version of the Caprini score and its modifications considering the elevation of D-dimer and specific COVID-19 points demonstrated a significant association with symptomatic VTE and unfavorable outcome in 168 hospitalized COVID-19 patients, of whom 6.5% developed symptomatic VTE and 18.5% - unfavorable outcome despite routine pharmacoprophylaxis.Take Home Message The Caprini score allows stratification of COVID-19 inpatients according to their VTE risk and identification of subjects at extremely high risk.TABLE OF CONTENTS SUMMARY This retrospective analysis of prospectively collected data demonstrates the significant association between the original and modified Caprini score and symptomatic VTE or unfavorable outcome in 168 patients with confirmed COVID-19. The Caprini score may be used for VTE risk assessment, and identification of persons at extremely high risk among COVID-19 patients admitted to the hospital.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study has a retrospective character and was not previously registered because it appeared urgently during the COVID-19 pandemic.Funding StatementThe study was performed without any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No need for ethical approval and a waiver of informed consent because of the retrospective character of the analysis in the urgent situation was confirmed by the Institutional Review Board of Clinical Hospital no.1 of the President's Administration of the Russian Federation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data set is available by the request to the corresponding author.